Treatt Posts Sharp Profit Drop in Challenging Year Amid Takeover Fallout

Quick take: tough year, clearer runway

Treatt’s FY25 numbers are down sharply, but broadly in line with July’s revised guidance. Revenue fell 11.8% and profits were hit harder by margin pressure and softer US demand. A potential takeover bid fell away after a large customer-shareholder built a 28% stake, and the Board has now formalised a relationship agreement to safeguard arm’s-length dealings.

Under the bonnet, there is disciplined cost control, expanding international reach, and a growing pipeline. The dividend has been cut to reflect lower earnings, and net debt crept up mainly due to last year’s £5.0 million buyback. FY26 has started “in line” with expectations.

Key numbers investors will care about

Metric	FY25	FY24 (restated)
Revenue	£132.5m	£150.2m
Gross margin	25.9%	29.3%
Adjusted EBITDA	£16.2m	£24.4m
Profit before tax (pre-exceptional)	£10.3m	£18.5m
Statutory profit before tax	£7.0m	£17.9m
Adjusted basic EPS	13.40p	23.58p
Basic EPS	8.38p	22.71p
Total dividend per share	5.60p	8.41p
Net debt	£5.9m	£0.7m
Adjusted net operating margin	8.1%	12.9%
Adjusted ROACE	7.5%	13.3%

What drove the decline: citrus costs and US softness

Citrus remains half the business by revenue. Sustained high citrus prices squeezed margins and changed buying patterns, with some customers reducing volumes. Citrus revenue fell 11.2% (£8.1m). Synthetic aroma saw lower prices with flat volumes. The premium segment – tea, health & wellness, and fruit & veg – declined 13.3% to £30.0m, despite an “exciting win” in sugar reduction.

Geographically, the US – 40% of Group revenue – slipped 7.8% to £53.0m on weaker consumer demand and lower ready-to-drink coffee volumes. Europe was also affected by citrus dynamics, while Asia excluding China grew, lifting “Rest of the world” to £23.9m. China declined 16.8% to £9.6m as elevated citrus prices persisted and competition intensified.

Gross margin dropped 340bps to 25.9%, a sizeable compression in a product-led business. Cost discipline helped – admin costs (ex-exceptionals) fell 4.1% and headcount reduced from 379 to 353 – but couldn’t fully offset the top-line and margin pressure.

Cash, debt and dividend: conserving while investing

Net debt at year end was £5.9m (FY24: £0.7m), reflecting the completed £5.0m share buyback and weaker H2 trading. Cash generated from operating activities fell to £11.3m from £21.1m, impacted by lower profitability and higher inventories (£62.5m, up £7.6m) driven by citrus inflation and reduced volumes.

The dividend is reset: 3.00p proposed final, 5.60p total for the year, offering 1.5x cover on statutory earnings (around 2.4x before exceptional items). To my mind, that’s prudent until margins and earnings stabilise.

On liquidity, Treatt retains strong facilities and covenant headroom: a £25.0m UK asset-based lending facility (with a £10.0m accordion) extended to June 2027, and a $25.0m US revolver expected to extend to July 2027. Interest cover before exceptionals was 30.1x, comfortably above covenant levels.

Governance and the lapsed bid: what Döhler’s stake means

Natara Global’s bid lapsed in November due to insufficient support after Döhler Group SE accumulated 28% of the shares. Treatt has signed a Relationship Agreement with Döhler Finance Management B.V., giving Döhler the right to appoint one director while requiring all dealings to be at arm’s length and on normal commercial terms. Helga Moelschl joins as a non-Independent Non-executive Director on 1 February 2026 under this arrangement.

Why it matters: balancing a large strategic shareholder that is also a customer can bring commercial opportunities, but conflicts must be carefully managed. The formal agreement and Board oversight are there to protect minority investors while potentially unlocking growth.

Operational progress and growth investments

• Commercial momentum in health & wellness: a notable win in sugar reduction, a high-value category with structural tailwinds.
• European push: expanded sales teams in Germany and France to deepen regional reach.
• Asia acceleration: new commercial and innovation centre launched in Shanghai (Dec 2025), plus a South-East Asia distribution agreement with IMCD signed post year end.
• Cost and efficiency: tighter spend, regional restructure, and ongoing operational efficiency work to protect margins without starving innovation.

On strategy, the focus is clear: be the partner of choice in high-growth beverage niches where flavour, functionality and quality intersect, while digitising platforms and using AI to speed product development and operations. Medium-term, management still targets a 15% adjusted net operating margin. With well-invested facilities in the UK and US and capacity to absorb growth, operating leverage is a genuine upside if revenue recovers.

Pension risk reduced: buy-in completed

The defined benefit scheme has been de-risked with an insurance buy-in completed in December 2025 with Just. The scheme is fully funded and no further employer contributions are being made. Exceptional costs were modest and primarily related to transaction fees.

My read of the risk-reward

Negatives first: earnings compression from citrus costs and US demand, a lower dividend, higher inventories tying up cash, and leadership transitions (CEO and CFO roles to fill permanently). The restatement of FY24 revenue is not material, but it is another housekeeping item investors will clock.

The positives: a resilient balance sheet with ample facilities, disciplined cost control, a growing pipeline, and tangible growth actions in Europe and Asia. The sugar reduction win signals relevance in a category that should outgrow the wider market. If citrus pricing normalises and US demand steadies, the margin rebuild could be meaningful given Treatt’s operational gearing.

Net-net, this is a reset year that preserves optionality. Execution on pipeline conversion, inventory normalisation, and a successful leadership handover are the near-term swing factors.

Jargon buster

• Adjusted EBITDA: earnings before interest, tax, depreciation and amortisation, excluding exceptional items – a proxy for cash operating profit.
• Basis points (bps): one hundredth of a percentage point. 340bps equals 3.40 percentage points.
• ROACE: return on average capital employed – how efficiently profits are generated from the capital in the business.
• Buy-in (pension): an insurance policy purchased by the scheme to match liabilities, reducing risk to the employer.
• Asset-based lending (ABL): a facility secured against assets like inventory and receivables.

What to watch next

• Trading pace in FY26 H1 – management says it is in line with expectations.
• Citrus price trends and margin recovery – the big driver for gross margin.
• Pipeline conversion in sugar reduction, tea and botanicals – revenue mix matters as much as volume.
• Inventory run-down and cash generation – working capital discipline to rebuild net cash.
• Permanent CEO and CFO appointments – leadership clarity and continuity.
• Impact of the IMCD South-East Asia deal and the Shanghai centre on Asia growth.
• Governance in practice with Döhler – arm’s-length transactions and broader collaboration.

Want the company’s own walkthrough?

Treatt has a pre-recorded results presentation here: financial results webcasts.